Title: Screening for Colorectal Cancer - Blood-Based Biomarker Tests (CAG-00454N)

Decision: The Centers for Medicare & Medicaid Services (CMS) has determined that the evidence is sufficient to cover a blood-based biomarker test as an appropriate colorectal cancer screening test once every 3 years for Medicare beneficiaries when performed in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory, when ordered by a treating physician and when all applicable coverage requirements are met.

The currently available Epi proColon[®] test does not meet the criteria for an appropriate blood-based biomarker CRC screening test. Based on the evidence at this time, CMS will non-cover the Epi proColon[®] test.

What this means: A blood-based biomarker lab test may be covered every 3 years to screen for colorectal cancer when coverage requirements are met. Please refer to the final decision memo for all coverage criteria. The Epi proColon[®] test is not covered.

Effective: January 19, 2021

This announcement can be found at: <u>Decision Memo for Screening for</u> <u>Colorectal Cancer - Blood-Based Biomarker Tests (CAG-00454N)</u>

HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners is also a Cost plan and PPO plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal. HealthPartners UnityPoint Health is a PPO plan with a Medicare contract. Enrollment in HealthPartners UnityPoint Health depends on contract renewal.

H2462_90242 IR Approved 06/2015 H3416_90242 IR Approved 06/2017 H2422_90242 IR Approved 07/2015 H4882_90242 IR Approved 03/2018